SciELO - Scientific Electronic Library Online

 
vol.27 número3Estenosis ureteral post-trasplante renal: tratamiento con prótesis metálica autoexpandibleFinasterida: diez años de uso clínico. Revisión sistemática de la literatura índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

Links relacionados

Compartir


Actas Urológicas Españolas

versión impresa ISSN 0210-4806

Resumen

MILLAN RODRIGUEZ, F.; ROUSAUD BARON, F.  y  ROUSAUD BARON, A.. Model study of the treatment of recurrent cystitis in women by means of AM3 (Inmunoferon®). Actas Urol Esp [online]. 2003, vol.27, n.3, pp.196-201. ISSN 0210-4806.

OBJECTIVES: The aim is to evaluate the effectiveness of AM3 (Inmunoferon®) in the treatment of the recurrent cystitis in women in order to know the rate of good results, previously to design a clinical trial. MATERIAL AND METHODS: Twenty-four women who had been diagnosed of two cystitis episodes in the previous 6 months without cure by antibiotic treatment were admitted to the study. Standard antibiotic treatment and 3 daily grammes of AM3 was given for 9 months. Infection and irritative symptoms during micturition rate were evaluated at the inclusion date and afterwards, at the first, third, sixth and nineth month. RESULTS: Nineteen patients finished the study. The infection rate decreased from 100% at the inclusion date to 26% in the first month and then it became stable about 50%. Irritative symptoms during micturition decreased from 46% at the inclusion date to a rate lower than 10% in the 4 controls running. CONCLUSION: AM3 reduced evident urinary infection in a 50% and irritative symptoms during micturition in a 90%. Control clinical trials are needed to confirm the AM3 effects on this pathology.

Palabras clave : Recurrent cystitis; AM3; Inmunoferon®.

        · resumen en Español     · texto en Español     · Español ( pdf )

 

Creative Commons License Todo el contenido de esta revista, excepto dónde está identificado, está bajo una Licencia Creative Commons